Hot Products

Astaxanthin
Catalog No: CFN90096

Astaxanthin is a strong antioxidant which shows neuroprotective property and can reduce the markers of inflammation, it can reduce matrix metalloproteinase expression in human chondrocytes, it may be beneficial in the treatment of osteoarthritis.Astaxanthin has protective effect on fetal alcohol spectrum disorder, and suggests that oxidative stress and TLR4 signaling associated inflammatory reaction are involved in this process. Astaxanthin administration can reduce renal calcium oxalate crystal deposition possibly by modulating the renal renin-angiotensin system (RAS), which reduces the expression of OPN and TGF-β1 levels.

Astilbin
Catalog No: CFN98371

Astilbin has insecticidal, antioxidant, antibacterial, and anti-inflammatory activities, it may act as an efficient therapeutic agent for arthritis like cyclosporine A but with less toxicity, its mechanism includes a selective suppression on lymphocyte functions via reducing MMP and NO production. Astilbin can exert an early renal protective role to diabetic nephropathy (DN), inhibit production of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF).Astilbin also alleviates contact hypersensitivity through a unique mechanism involving a negative cytokine regulation through stimulating IL-10, which is distinct from the immunosuppressant cyclosporin A.

Astin A
Catalog No: CFN95187

Astin A has antitumor activity.

Astin B
Catalog No: CFN95188

Astin B has antitumor activity.

Astin C
Catalog No: CFN95189

Astin C has antitumor activity.

Astragalin
Catalog No: CFN98733

Astragalin (kaempferol-3-O-glucoside) is a flavonoid with anti-inflammatory activity, it inhibits the TLR4-mediated NF-κB and mitogen-activated protein kinases signaling pathways. Astragalin ameliorates oxidative stress-associated epithelial eosinophilia and apoptosis through disturbing TLR4-PKCβ2-NADPH oxidase-responsive signaling; it also can be effective in allaying ROS-promoted bronchial fibrosis through inhibiting autophagosome formation in airways.

Astragaloside
Catalog No: CFN99170

Astragaloside may protect against brain contusion and neuronal apoptosis after TBI by attenuating microglia activation in male rats. Astragalosides-induced apoptosis in NB4 cells may be associated with down-regulation of the expression of BCL-2 and NF-κB, finally the relative activity of caspase-3 activated. Astragaloside has several pharmacological actions on cardiovascular system, including positive inotropic, anti-arrhythmia and anti-oxidant activities; it also has anti-apoptotic activity, which may contribute to the improvement of clinical outcomes in treating myocarditis with pharmaceutics of Astragalus membranaceus.

Astragaloside I
Catalog No: CFN99172

Astragaloside Ι may protect the cerebral tissue against the free radical damage in ischemia and inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway. It stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway.

Astragaloside II
Catalog No: CFN99173

Astragaloside II is a potent autophagy inhibitor and multidrug resistance (MDR) reversal agent, which restores chemosensitivity of anticancer agent cisplatin and enhances tumor cell death. It has immunomodulating activity, can trigger T cell activation through regulation of CD45 protein tyrosine phosphatase activity, it induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

Astragaloside III
Catalog No: CFN99174

Astragaloside III has anti-gastric ulcer effects, and exhibits strong growth-promoting effects in cultured GES-1 cells. Astragaloside III can effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo, the potential mechanism is the induction of cell apoptosis signaling pathways, suggests that it provides a new therapeutic tool to treat breast cancer.